Presentation on theme: "Hepatitis Studies Shyam Kottilil M.D., Ph.D. Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases National Institutes of."— Presentation transcript:
Hepatitis Studies Shyam Kottilil M.D., Ph.D. Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Bethesda, MD
Hepatitis C and HIV coexist in the US Number affected (millions) HCV HIV Sulkowski MS, Mast EE, Seeff, LB et al. Hepatitis C Virus Infection as an Opportunistic Disease in Persons infected with Human Immunodeficiency Virus. Clin Infect Dis. 2000;30: Population All HIV Percentage IVDU 90% 33% Population
Washington, D.C. Our Nations Capital 3%=18000 HIV+ 1.8%=12000 HCV+
Establishment of Hepatitis Clinics Average Incidence Rate per 100,000 Population – – – – Numbers found below each ward refer to the rate of newly reported HIV cases per 100,000 population. Rates were calculated using 2000 Census data. For 16% of cases, ward information was not available and therefore not displayed on this map.
Hepatitis Treatment Protocols-DC-PFAP GS-7977+RBV Anti-fibrosis Jan Mar Sept Dec Mar June Sept HCV DAA Tx Peg+RBV+PI (Boc) IFN and RBV FREE Tx TLR7 PHASE 1 Anti-fibrosis HCV-DAA TLR7 Phase 1 Natural History Anti-fibrosis
Most Effective HIV Program Most Effective Hepatitis Program Washington, D.C. Our Nations Capital